The global human organoids market size is estimated to be USD 850 million in 2020 and projected to reach USD 1,901 million by 2025, at a CAGR of 17.5%.
Major Revenue Growth Boosters:
Increasing prevalence of transplantation, technological advancements and increased funding and public-private investments are the key factors driving the growth of the human organoids.
Market Size Estimation:
Both top-down and bottom-up approaches were used to estimate and validate the total size of the clinical microbiology market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
# The key players in the industry and markets have been identified through extensive secondary research
# The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research
# All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Download PDF Brochure@
Driver: Growing focus on developing alternatives for animal testing models
Animal models are widely used in biomedical research for human-specific diseases. However, there are various cases that demonstrate that animal models cannot always be predictive for human drug response, like in the case of drug toxicology studies. This is because there are wide variations in the metabolism of drugs and toxins in humans as compared to animals, which makes it nearly impossible to study drug metabolism in experimental models such as laboratory rodent species. Additionally, in recent years, several regulations have been implemented that restrict the use of animals in research activities globally. Similarly, several bodies, such as Cruelty Free International and the Fund for the Replacement of Animals in Medical Experiments, oppose the use of animal-based models for research purposes.
Restraint: Issues related to the incorporation of organoids into existing workflows
The lack of infrastructure for 3D cell culture research is significantly limiting the overall growth of the organoids market. The availability of the necessary equipment to use advanced techniques is one of the prerequisites for conducting 3D cell culture-based research. Moreover, various technical challenges are involved in incorporating organoids into existing research workflows as the manufacturing of organoids is capital- and time-intensive. Owing to this, the adoption of organoids in ongoing drug screening and drug discovery activities is limited. This is a major issue as the ongoing drug screening and drug discovery processes will take a long time (up to a few years) to complete.
Opportunity: Increasing focus on drug discovery activities
The increasing demand for new and advanced drugs is driving the overall pace of drug discovery and research. This is the major factor responsible for the rising number of clinical trials conducted for studying and commercializing new drugs. According to ClinicalTrials.gov, the total number of clinical trial studies in 2020 was estimated at 356,282.
A recent study conducted by the Hubrecht Institute states that organoids have the potential to make expensive drugs more cost-effective by identifying patients who are not likely to benefit from the drug. The significant growth in the number of clinical trials across the globe is expected to drive the demand for advanced medical technologies, including organoid models.
Challenge: Dearth of skilled professionals
Skilled professionals, such as researchers and technicians, are required to set up and run experiments involving organoids, and further make observations, obtain results, and analyze the obtained data. The lack of knowledge regarding the underlying scientific principles and the right choice of technique may result in several direct and indirect expenses and increase the workload and time pressure on researchers and service providers. Thus, there is a need for highly skilled personnel for interpretation, method development, validation, operation, and troubleshooting activities.
Request Sample Pages@
Pharceuticals & Biotechnology companies accounted for the largest share of the human organoids market, by end users, in 2020
Pharmaceutical and biotechnology companies mainly focus on developing new drugs for the treatment of various rare diseases. These companies need to submit specific data related to drug development during the drug development process and subsequent filing of applications to regulatory bodies. This necessitates a wide spectrum of services in the early development phases and clinical phases to comply with regulatory requirements. Technical and regulatory challenges related to the development of new drug molecules create complexities for pharmaceutical and biotechnology companies in terms of time and cost. However, due to strict regulations, companies often produce technologically superior products with better safety norms.